MedTrace Logo

Durvalumab and "Booster" Radiation in Metastatic Adenocarcinoma of the Pancreas

NCT03490760 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 9

Last updated 2023-10-12

Study results available
· View outcomes & findings →

Summary

This is a single-institution, single-arm phase II trial of Durvalumab combined with Radiation Therapy (RT) for metastatic pancreatic cancer patients who have progressed through first-line chemotherapy.

Conditions

  • Adenocarcinoma of the Pancreas

Interventions

DRUG

Durvalumab

Durvalumab 1500 mg (or 20 mg/m2 if \<30 kg) IV every 4 weeks

RADIATION

Radiation Therapy

24 Gy in 3 daily fractions to one lesion during Week 3 and 24 Gy in 3 daily fractions to the second lesion during Week 5.

Sponsors & Collaborators

  • AstraZeneca

    collaborator INDUSTRY

  • Baptist Health South Florida

    lead OTHER

Principal Investigators

  • Michael D. Chuong, MD · Miami Cancer Institute at Baptist Health, Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-11-09
Primary Completion
2020-07-09
Completion
2020-07-09
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03490760 on ClinicalTrials.gov